Cargando…

Dynamics of the gut-liver axis in rats with varying fibrosis severity

The classic carbon tetrachloride (CCl(4))-induced liver injury model is widely used to study the pathogenesis of fibrosis and evaluate anti-fibrosis drugs. Here, we investigated the dynamic changes in the gut microbiota, bile acids (BAs) and the gut barrier over different fibrosis severities in a CC...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Hongyan, Liu, Zongyi, Xiang, Huanyu, Xiang, Dejuan, Xiao, Shuang, Xiao, Jing, Shen, Wei, Hu, Peng, Ren, Hong, Peng, Mingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134918/
https://www.ncbi.nlm.nih.gov/pubmed/35637968
http://dx.doi.org/10.7150/ijbs.69833
_version_ 1784713855939641344
author Xiang, Hongyan
Liu, Zongyi
Xiang, Huanyu
Xiang, Dejuan
Xiao, Shuang
Xiao, Jing
Shen, Wei
Hu, Peng
Ren, Hong
Peng, Mingli
author_facet Xiang, Hongyan
Liu, Zongyi
Xiang, Huanyu
Xiang, Dejuan
Xiao, Shuang
Xiao, Jing
Shen, Wei
Hu, Peng
Ren, Hong
Peng, Mingli
author_sort Xiang, Hongyan
collection PubMed
description The classic carbon tetrachloride (CCl(4))-induced liver injury model is widely used to study the pathogenesis of fibrosis and evaluate anti-fibrosis drugs. Here, we investigated the dynamic changes in the gut microbiota, bile acids (BAs) and the gut barrier over different fibrosis severities in a CCl(4)-based model. 16S rDNA sequencing demonstrated that the beneficial taxon Lactobacillus was always underrepresented, and pathogens including Escherichia_Shigella, Clostridium_sensu_stricto_1, Colidextribacter, and Lachnospiraceae_UCG_010 were significantly overrepresented across liver fibrosis severities. Gut dysbiosis was more severe at the early stage of liver injury and advanced stage of fibrosis. An ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis revealed that with the progress of fibrosis, unconjugated BAs in faeces were significantly decreased and conjugated BAs in serum were significantly increased. The FXR-SHP signalling pathway in the liver and ileum was statistically repressed in the fibrosis groups. Determination of lipopolysaccharide (LPS) and fluorescein isothiocyanate (FITC)-dextran levels in plasma showed that the intestinal barrier remained relatively intact in the advanced fibrosis stage. The advances in knowledge of the gut-liver axis provided by this study yield new insights for application in research and drug evaluation.
format Online
Article
Text
id pubmed-9134918
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-91349182022-05-29 Dynamics of the gut-liver axis in rats with varying fibrosis severity Xiang, Hongyan Liu, Zongyi Xiang, Huanyu Xiang, Dejuan Xiao, Shuang Xiao, Jing Shen, Wei Hu, Peng Ren, Hong Peng, Mingli Int J Biol Sci Research Paper The classic carbon tetrachloride (CCl(4))-induced liver injury model is widely used to study the pathogenesis of fibrosis and evaluate anti-fibrosis drugs. Here, we investigated the dynamic changes in the gut microbiota, bile acids (BAs) and the gut barrier over different fibrosis severities in a CCl(4)-based model. 16S rDNA sequencing demonstrated that the beneficial taxon Lactobacillus was always underrepresented, and pathogens including Escherichia_Shigella, Clostridium_sensu_stricto_1, Colidextribacter, and Lachnospiraceae_UCG_010 were significantly overrepresented across liver fibrosis severities. Gut dysbiosis was more severe at the early stage of liver injury and advanced stage of fibrosis. An ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis revealed that with the progress of fibrosis, unconjugated BAs in faeces were significantly decreased and conjugated BAs in serum were significantly increased. The FXR-SHP signalling pathway in the liver and ileum was statistically repressed in the fibrosis groups. Determination of lipopolysaccharide (LPS) and fluorescein isothiocyanate (FITC)-dextran levels in plasma showed that the intestinal barrier remained relatively intact in the advanced fibrosis stage. The advances in knowledge of the gut-liver axis provided by this study yield new insights for application in research and drug evaluation. Ivyspring International Publisher 2022-05-09 /pmc/articles/PMC9134918/ /pubmed/35637968 http://dx.doi.org/10.7150/ijbs.69833 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Xiang, Hongyan
Liu, Zongyi
Xiang, Huanyu
Xiang, Dejuan
Xiao, Shuang
Xiao, Jing
Shen, Wei
Hu, Peng
Ren, Hong
Peng, Mingli
Dynamics of the gut-liver axis in rats with varying fibrosis severity
title Dynamics of the gut-liver axis in rats with varying fibrosis severity
title_full Dynamics of the gut-liver axis in rats with varying fibrosis severity
title_fullStr Dynamics of the gut-liver axis in rats with varying fibrosis severity
title_full_unstemmed Dynamics of the gut-liver axis in rats with varying fibrosis severity
title_short Dynamics of the gut-liver axis in rats with varying fibrosis severity
title_sort dynamics of the gut-liver axis in rats with varying fibrosis severity
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134918/
https://www.ncbi.nlm.nih.gov/pubmed/35637968
http://dx.doi.org/10.7150/ijbs.69833
work_keys_str_mv AT xianghongyan dynamicsofthegutliveraxisinratswithvaryingfibrosisseverity
AT liuzongyi dynamicsofthegutliveraxisinratswithvaryingfibrosisseverity
AT xianghuanyu dynamicsofthegutliveraxisinratswithvaryingfibrosisseverity
AT xiangdejuan dynamicsofthegutliveraxisinratswithvaryingfibrosisseverity
AT xiaoshuang dynamicsofthegutliveraxisinratswithvaryingfibrosisseverity
AT xiaojing dynamicsofthegutliveraxisinratswithvaryingfibrosisseverity
AT shenwei dynamicsofthegutliveraxisinratswithvaryingfibrosisseverity
AT hupeng dynamicsofthegutliveraxisinratswithvaryingfibrosisseverity
AT renhong dynamicsofthegutliveraxisinratswithvaryingfibrosisseverity
AT pengmingli dynamicsofthegutliveraxisinratswithvaryingfibrosisseverity